Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Harold S. who wrote (14291)	2/5/1998 2:05:00 PM
From: squetch	Respond to of 32384

Harold, I am a LGND Lifer, so I am the wrong one to ask. I am still looking to add some warrants, but am expecting more weakness. I would like to see a day like 4/25/97 to confirm the end of this downtrend. squetch

To: Harold S. who wrote (14291)	2/5/1998 4:10:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Harold, LGND has good news for long and short term players. Currently the price is very low, so it's relatively easy to make significant moves from these levels. I talked to IR earlier this week. The NDA for Panretin topical for KS is "on track" for this quarter. This will be LGND's first NDA, so it should be significant (although it is widely expected). LGND also expect to release strong clinicals for treatment of major cancer markets (KS which may translate into HIV+, prostate, and ovarian cancer - clinical presentations are planned for April, May, and June). AHP's IND for TSE424 is also slated for this quarter (but an announcement is dependent on AHP, not LGND). Bear Stearns provided new estimates on Dec 31, 1997, and they expected profitability next year. Several additional analysts should be putting out revised numbers soon (consistant with Bear Stearns' positive revisions).